奥雷巴替尼联合维奈克拉及减低强度化疗治疗成人初诊费城染色体阳性急性淋巴细胞白血病:一项单中心、单臂、2期试验
这项单中心、单臂、2期试验纳入79例中位年龄42岁的初诊费城染色体阳性急性淋巴细胞白血病成人患者,自2022年10月至2024年3月接受奥雷巴替尼联合维奈克拉及减低强度化疗,主要终点为3个月完全分子学缓解率。3个月完全分子学缓解率为62.0%,诱导期无死亡;中位随访12个月,估计1年总生存率和无事件生存率分别为93.1%(95%CI 86.4-99.8)和89.1%(95%CI 80.3-97.9)。
要点
- 3个月完全分子学缓解率为62.0%,未使用强化化疗或免疫治疗。
- 诱导期无死亡,中位随访12个月估计1年总生存率93.1%。
- 估计1年无事件生存率为89.1%(95%CI 80.3-97.9)。
核心结论
- 奥雷巴替尼联合维奈克拉及减低强度化疗为初诊费城染色体阳性急性淋巴细胞白血病患者提供了替代治疗策略,尤其适用于初始阶段不适合或无法获得免疫治疗或强化化疗的患者。
研究设计与样本
- 单中心、单臂、2期前瞻性临床试验,自2022年10月至2024年3月纳入79例中位年龄42岁的初诊费城染色体阳性急性淋巴细胞白血病成人患者,完成至少3个周期奥雷巴替尼和维奈克拉为基础方案。
主要发现
- 3个月完全分子学缓解率为62.0%,未使用强化化疗或免疫治疗。
- 诱导期无死亡。
- 中位随访12个月,估计1年总生存率为93.1%(95%CI 86.4-99.8),估计1年无事件生存率为89.1%(95%CI 80.3-97.9)。
- 转录组数据揭示酪氨酸激酶抑制剂与维奈克拉之间可能存在互补机制,验证了两药联合的依据。
关键数值与推荐
- 主要终点为3个月完全分子学缓解率,结果为62.0%。
- 估计1年总生存率为93.1%(95%CI 86.4-99.8),估计1年无事件生存率为89.1%(95%CI 80.3-97.9)。
临床怎么用
- 作者认为该方案为初诊费城染色体阳性急性淋巴细胞白血病患者提供了替代治疗策略,尤其适用于初始阶段不适合或无法获得免疫治疗或强化化疗的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tyrosine kinase inhibitors (TKIs) combined with chemotherapy and immunotherapy evolved as the standard treatment for newly diagnosed (ND) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nonetheless, the efficacy and safety of combining TKIs with BCL-2 inhibitors in ND Ph+ ALL have yet to be fully elucidated. Hence, we carried out a prospective clinical trial to explore the efficacy and safety of olverembatinib combined with venetoclax and reduced-intensity chemotherapy as frontline treatment in Ph+ ALL. From October 2022 to March 2024, a total of 79 patients with a median age of 42 years completed a minimum of three cycles of olverembatinib and venetoclax-based regimen. The primary end point of the study was the complete molecular response (CMR) rate at 3 months. Ultimately, the regimen achieved CMR of 62.0% at 3 months in the absence of intensive chemotherapy or immunotherapy. No deaths occurred during the induction phase. With a median follow-up of 12 months, the estimated 1-year overall survival (OS) and event-free survival (EFS) rates were 93.1% (95% CI 86.4-99.8) and 89.1% (95% CI 80.3-97.9), respectively. Transcriptomic data revealed a potential complementary mechanism between TKIs and venetoclax, thereby verifying the rationale for the combination of these two agents. In conclusion, our study provides an alternative treatment strategy for patients with ND Ph+ ALL, particularly for those who are unfit or unavailable for immunotherapy or intensive chemotherapy at the initial stage of treatment. Clinical trial registration: The study was registered at https://clinicaltrials.gov/ with the registration number of NCT05594784.
引用
- Gong X, Liu W, Liu Y, et al. Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial. Leukemia. 2025. PMID: 40588568. doi:10.1038/s41375-025-02674-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。